Talazoparib is indicated as monotherapy for the treatment of adult patients with germline BRCA1/2 mutations, who have HER2-negative locally advanced or metastatic breast cancer.
| NCPE Assessment Process | Complete |
| Rapid review commissioned | 19/08/2019 |
| Rapid review completed | 03/09/2019 |
| Rapid Review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of talazoparib compared with the current standard of care. |